These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 8565307)

  • 1. Ivermectin-induced immunopotentiation in onchocerciasis: recognition of selected antigens following a single dose of ivermectin.
    Akuffo H; Maasho K; Lavebratt C; Engström K; Britton S
    Clin Exp Immunol; 1996 Feb; 103(2):244-52. PubMed ID: 8565307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection.
    Soboslay PT; Lüder CG; Hoffmann WH; Michaelis I; Helling G; Heuschkel C; Dreweck CM; Blanke CH; Pritze S; Banla M
    Clin Exp Immunol; 1994 May; 96(2):238-44. PubMed ID: 8187332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoregulation in onchocerciasis: predominance of Th1-type responsiveness to low molecular weight antigens of Onchocerca volvulus in exposed individuals without microfilaridermia and clinical disease.
    Lüder CG; Schulz-Key H; Banla M; Pritze S; Soboslay PT
    Clin Exp Immunol; 1996 Aug; 105(2):245-53. PubMed ID: 8706329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection.
    Soboslay PT; Geiger SM; Weiss N; Banla M; Lüder CG; Dreweck CM; Batchassi E; Boatin BA; Stadler A; Schulz-Key H
    Immunology; 1997 Apr; 90(4):592-9. PubMed ID: 9176114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.
    Mai CS; Hamm DM; Banla M; Agossou A; Schulz-Key H; Heuschkel C; Soboslay PT
    Clin Exp Immunol; 2007 Mar; 147(3):504-12. PubMed ID: 17302900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo.
    Johanns SI; Gantin RG; Wangala B; Komlan K; Halatoko WA; Banla M; Karabou P; Luty AJ; Schulz-Key H; Köhler C; Soboslay PT
    PLoS Negl Trop Dis; 2022 May; 16(5):e0010340. PubMed ID: 35503786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemokines in onchocerciasis patients after a single dose of ivermectin.
    Fendt J; Hamm DM; Banla M; Schulz-Key H; Wolf H; Helling-Giese G; Heuschkel C; Soboslay PT
    Clin Exp Immunol; 2005 Nov; 142(2):318-26. PubMed ID: 16232219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunocompetence may be important in the effectiveness of Mectizan (ivermectin) in the treatment of human onchocerciasis.
    Ali MM; Mukhtar MM; Baraka OZ; Homeida MM; Kheir MM; Mackenzie CD
    Acta Trop; 2002 Oct; 84(1):49-53. PubMed ID: 12387910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin.
    Komlan K; Vossberg PS; Gantin RG; Solim T; Korbmacher F; Banla M; Padjoudoum K; Karabou P; Köhler C; Soboslay PT
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006312. PubMed ID: 29494606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of onchocerciasis.
    Van Laethem Y; Lopes C
    Drugs; 1996 Dec; 52(6):861-9. PubMed ID: 8957156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of ivermectin treatment on the antibody response to antigens of Onchocerca volvulus.
    Gillespie AJ; Lustigman S; Rivas-Alcala AR; Bradley JE
    Trans R Soc Trop Med Hyg; 1994; 88(4):456-60. PubMed ID: 7570844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxycycline Leads to Sterility and Enhanced Killing of Female Onchocerca volvulus Worms in an Area With Persistent Microfilaridermia After Repeated Ivermectin Treatment: A Randomized, Placebo-Controlled, Double-Blind Trial.
    Debrah AY; Specht S; Klarmann-Schulz U; Batsa L; Mand S; Marfo-Debrekyei Y; Fimmers R; Dubben B; Kwarteng A; Osei-Atweneboana M; Boakye D; Ricchiuto A; Büttner M; Adjei O; Mackenzie CD; Hoerauf A
    Clin Infect Dis; 2015 Aug; 61(4):517-26. PubMed ID: 25948064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.
    Gardon J; Gardon-Wendel N; Demanga-Ngangue ; Kamgno J; Chippaux JP; Boussinesq M
    Lancet; 1997 Jul; 350(9070):18-22. PubMed ID: 9217715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of an Onchocerca ochengi microfilarial hamster model for onchocerciasis drug screens.
    Mbah GE; Ayiseh RB; Cho-Ngwa F
    BMC Infect Dis; 2016 Aug; 16(1):404. PubMed ID: 27515037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus.
    Osei-Atweneboana MY; Awadzi K; Attah SK; Boakye DA; Gyapong JO; Prichard RK
    PLoS Negl Trop Dis; 2011 Mar; 5(3):e998. PubMed ID: 21468315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproductive status of Onchocerca volvulus after ivermectin treatment in an ivermectin-naïve and a frequently treated population from Cameroon.
    Nana-Djeunga HC; Bourguinat C; Pion SD; Bopda J; Kengne-Ouafo JA; Njiokou F; Prichard RK; Wanji S; Kamgno J; Boussinesq M
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2824. PubMed ID: 24762816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient changes in cytokine profiles following ivermectin treatment of onchocerciasis.
    Steel C; Lujan-Trangay A; Gonzalez-Peralta C; Zea-Flores G; Nutman TB
    J Infect Dis; 1994 Oct; 170(4):962-70. PubMed ID: 7930742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental onchocerciasis in chimpanzees. Antibody response and antigen recognition after primary infection with Onchocerca volvulus.
    Soboslay PT; Weiss N; Dreweck CM; Taylor HR; Brotman B; Schulz-Key H; Greene BM
    Exp Parasitol; 1992 Jun; 74(4):367-80. PubMed ID: 1592090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chemotherapy of onchocerciasis. XIII. Studies with ivermectin in onchocerciasis patients in northern Ghana, a region with long lasting vector control.
    Awadzi K; Dadzie KY; Kläger S; Gilles HM
    Trop Med Parasitol; 1989 Sep; 40(3):361-6. PubMed ID: 2694315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin.
    Pion SD; Grout L; Kamgno J; Nana-Djeunga H; Boussinesq M
    Acta Trop; 2011 Sep; 120 Suppl 1():S91-9. PubMed ID: 20497765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.